Heart failure: beta-blockers reduce all-cause mortality in patients with preserved ejection fraction

  • Heart

  • from Sarfaroj Khan
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients with heart failure and a left ventricular (LV) ejection fraction ≥40%, beta-blockers reduced all-cause and cardiovascular mortality by 22% and 25%, respectively.
  • Angiotensin-converting-enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB) and mineralocorticoid receptor antagonist (MRA) showed no significant effects on the same outcomes.

Why this matters

  • Beta-blockers should be considered by physicians when there is an existing indication for them.

Key results

  • Compared with placebo, beta-blockers reduced the risk for all-cause (relative risk [RR], 0.78; P=.008) and cardiovascular mortality (RR, 0.75; P=.01).
  • Compared with placebo, pooled analysis of ACE inhibitor (RR, 1.10; P=.46; n=1234), ARB (RR, 1.02; P=.71; n=7257) and MRA (RR, 0.92; P=.32; n=3867) trials showed no effect on all-cause mortality.

Study design

  • 25 randomised controlled trials involving 18,101 patients with heart failure with LV ejection fraction ≥40% met eligibility criteria after a search on Medline, EMBASE and the Cochrane Central Register of Controlled Trials.
  • Funding: British Heart Foundation.

Limitations

  • Lack of data on patients with an LV ejection fraction between 40% and 49%.